Journal of Vaccine Research, 2025, Vol.15, No.1, 34-44 http://medscipublisher.com/index.php/jvr 43 Logunov D.Y., Dolzhikova I.V., Zubkova O.V., Tukhvatulin A., Shcheblyakov D., Dzharullaeva A., Grousova D., Erokhova A., Kovyrshina A., Botikov A., Izhaeva F., Popova O., Ozharovskaya T., Esmagambetov I., Favorskaya I., Zrelkin D., Voronina D., Shcherbinin D., Semikhin A., Simakova Y., Tokarskaya E., Lubenets N., Egorova D., Shmarov M., Nikitenko N., Morozova L., Smolyarchuk E., Kryukov E., Babira V., Borisevich S., Naroditsky B., and Gintsburg A., 2020, Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia, Lancet, 396(10255): 887-897. https://doi.org/10.1016/S0140-6736(20)31866-3 Madewell Z.J., Dean N.E., Berlin J.A., Coplan P., Davis K., Struchiner C., and Halloran M., 2021, Challenges of evaluating and modelling vaccination in emerging infectious diseases, Epidemics, 37: 100506. https://doi.org/10.1016/j.epidem.2021.100506 McCann N., O’Connor D., Lambe T., and Pollard A., 2022, Viral vector vaccines, Current Opinion in Immunology, 77: 102210. https://doi.org/10.1016/j.coi.2022.102210 Mourosi J., Awe A., Jain S., and Batra H., 2022, Nucleic acid vaccine platform for DENGUE and ZIKA flaviviruses, Vaccines, 10(6): 834. https://doi.org/10.3390/vaccines10060834 Näslund J., Ahlm C., Islam K., Evander M., Bucht G., and Lwande O., 2021, Emerging mosquito-borne viruses linked to aedes aegypti and aedes albopictus: global status and preventive strategies, Vector borne and Zoonotic Diseases, 21(10): 731-746. https://doi.org/10.1089/vbz.2020.2762 Pitisuttithum P., and Marovich M.A., 2020, Prophylactic HIV vaccine: vaccine regimens in clinical trials and potential challenges, Expert Review of Vaccines, 19(2): 133-142. https://doi.org/10.1080/14760584.2020.1718497 Poland G., Kennedy R., Ovsyannikova I., Palacios R., Ho P., and Kalil J., 2018, Development of vaccines against zika virus, The Lancet, Infectious Diseases, 18(7): e211-e219. https://doi.org/10.1016/S1473-3099(18)30063-X Principi N., and Esposito S., 2024, Development of vaccines against emerging mosquito-vectored arbovirus infections, Vaccines, 12(1): 87. https://doi.org/10.3390/vaccines12010087 Ramachandran S., Satapathy S.R., and Dutta T., 2022, Delivery strategies for mRNA vaccines, Pharmaceutical Medicine, 36(1): 11-20. https://doi.org/10.1007/s40290-021-00417-5 Redoni M., Yacoub S., Rivino L., Giacobbe D., Luzzati R., and Di Bella S., 2020, Dengue: status of current and under‐development vaccines, Reviews in Medical Virology, 30(4): e2101. https://doi.org/10.1002/rmv.2101 Rosenberg R., Lindsey N., Fischer M., Gregory C., Hinckley A., Mead P., Paz-Bailey G., Waterman S., Drexler N., Kersh G., Hooks H., Partridge S., Visser S., Beard C., and Petersen L., 2018, Vital signs: trends in reported vectorborne disease cases-united states and territories, 2004-2016, Morbidity and Mortality Weekly Report, 67(17): 496-501. https://doi.org/10.15585/mmwr.mm6717e1 Rothen D.A., Dutta S.K., Krenger P.S., Pardini A., Vogt A.C.S., Josi R., Liekniņa I., Osterhaus A., Mohsen M., Vogel M., Martina B., Tārs K., and Bachmann M., 2024, Preclinical development of a novel zika virus-like particle vaccine in combination with tetravalent dengue virus-like particle vaccines, Vaccines, 12(9): 1053. https://doi.org/10.3390/vaccines12091053 Sayedahmed E.E., Gairola V., Murala M.S.T., and Mittal S.K., 2025, Bovine adenoviral vector-based platform for vaccine development, Vaccines, 13(5): 494. https://doi.org/10.3390/vaccines13050494 Socha W., Kwasnik M., Larska M., Rola J., and Rożek W., 2022, Vector-borne viral diseases as a current threat for human and animal health-one health perspective, Journal of Clinical Medicine, 11(11): 3026. https://doi.org/10.3390/jcm11113026 Straeten V., Sarmadi M., Daristotle J., Kanelli M., Tostanoski L., Collins J., Pardeshi A., Han J., Varshney D., Eshaghi B., Garcia J., Forster T.A., Li G., Menon N., Pyon S., Zhang L., Jacob-Dolan C., Powers O., Hall K., Alsaiari S., Wolf M., Tibbitt M., Farra R., Barouch D., Langer R., and Jaklenec A., 2023, A microneedle vaccine printer for thermostable COVID-19 mRNA vaccines, Nature Biotechnology, 42(3): 510-517. https://doi.org/10.1038/s41587-023-01774-z Szabó G., Mahiny A., and Vlatkovic I., 2022, COVID-19 mRNA vaccines: platforms and current developments, Molecular Therapy, 30(5): 1850-1868. https://doi.org/10.1016/j.ymthe.2022.02.016 Tang J., Amin M., and Campian J., 2025, Past, present, and future of viral vector vaccine platforms: a comprehensive review, Vaccines, 13(5): 524. https://doi.org/10.3390/vaccines13050524 Uddin M.N., and Roni M., 2021, Challenges of storage and stability of mRNA-Based COVID-19 vaccines, Vaccines, 9(9): 1033. https://doi.org/10.3390/vaccines9091033 Voss G., Casimiro D., Neyrolles O., Williams A., Kaufmann S., McShane H., Hatherill M., and Fletcher H., 2018, Progress and challenges in TB vaccine development, F1000Research, 7: 199. https://doi.org/10.12688/f1000research.13588.1 Wang S., Liang B., Wang W.Q., Li L., Feng N., Zhao Y., Wang T., Yan F.H., Yang S., and Xia X., 2023, Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases, Signal Transduction and Targeted Therapy, 8(1): 149. https://doi.org/10.1038/s41392-023-01408-5
RkJQdWJsaXNoZXIy MjQ4ODYzNA==